Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib

Camillo Porta, Chiara Paglino, Mara De Amici, Silvana Quaglini, Lucia Sacchi, Ilaria Imarisio, Cinzia Canipari

Research output: Contribution to journalArticle

Abstract

To identify factors that might predict response to sunitinib in patients with renal cell carcinoma, we measured serum vascular endothelial growth factor (VEGF) and neutrophil gelatinase-associated lipocalin (NGAL) levels. A total of 85 patients were selected and, using the Motzer classification, 46 were assigned to the good-and 38 to the intermediate-risk groups. With univariate Cox analysis, both baseline serum VEGF and NGAL titers, determined by enzyme-linked immunosorbent assay, significantly predicted progression-free survival. For each biomarker, a threshold value was identified, which proved useful to classify patients into groups having titers above or below the thresholds. We then stratified patients according to the two dichotomous variables into good-, intermediate-, and poor-risk groups, and found significantly different progression-free survival rates ranging from 3.5 to 11.6 months. Both VEGF and NGAL maintained their predictive significance at bivariate analysis. Our study shows that serum levels of VEGF and NGAL are significant predictors of progression-free survival in patients with renal cell carcinoma treated with sunitinib.

Original languageEnglish
Pages (from-to)809-815
Number of pages7
JournalKidney International
Volume77
Issue number9
DOIs
Publication statusPublished - May 2010

Fingerprint

Kidney Neoplasms
Vascular Endothelial Growth Factor A
Disease-Free Survival
Serum
Renal Cell Carcinoma
Survival Rate
Biomarkers
Enzyme-Linked Immunosorbent Assay
sunitinib
Lipocalin-2

Keywords

  • NGAL
  • Predictive factors
  • RCC
  • Sunitinib
  • VEGF

ASJC Scopus subject areas

  • Nephrology

Cite this

@article{a5866239b3d547eb8f139f6ebf8f64e8,
title = "Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib",
abstract = "To identify factors that might predict response to sunitinib in patients with renal cell carcinoma, we measured serum vascular endothelial growth factor (VEGF) and neutrophil gelatinase-associated lipocalin (NGAL) levels. A total of 85 patients were selected and, using the Motzer classification, 46 were assigned to the good-and 38 to the intermediate-risk groups. With univariate Cox analysis, both baseline serum VEGF and NGAL titers, determined by enzyme-linked immunosorbent assay, significantly predicted progression-free survival. For each biomarker, a threshold value was identified, which proved useful to classify patients into groups having titers above or below the thresholds. We then stratified patients according to the two dichotomous variables into good-, intermediate-, and poor-risk groups, and found significantly different progression-free survival rates ranging from 3.5 to 11.6 months. Both VEGF and NGAL maintained their predictive significance at bivariate analysis. Our study shows that serum levels of VEGF and NGAL are significant predictors of progression-free survival in patients with renal cell carcinoma treated with sunitinib.",
keywords = "NGAL, Predictive factors, RCC, Sunitinib, VEGF",
author = "Camillo Porta and Chiara Paglino and {De Amici}, Mara and Silvana Quaglini and Lucia Sacchi and Ilaria Imarisio and Cinzia Canipari",
year = "2010",
month = "5",
doi = "10.1038/ki.2009.552",
language = "English",
volume = "77",
pages = "809--815",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib

AU - Porta, Camillo

AU - Paglino, Chiara

AU - De Amici, Mara

AU - Quaglini, Silvana

AU - Sacchi, Lucia

AU - Imarisio, Ilaria

AU - Canipari, Cinzia

PY - 2010/5

Y1 - 2010/5

N2 - To identify factors that might predict response to sunitinib in patients with renal cell carcinoma, we measured serum vascular endothelial growth factor (VEGF) and neutrophil gelatinase-associated lipocalin (NGAL) levels. A total of 85 patients were selected and, using the Motzer classification, 46 were assigned to the good-and 38 to the intermediate-risk groups. With univariate Cox analysis, both baseline serum VEGF and NGAL titers, determined by enzyme-linked immunosorbent assay, significantly predicted progression-free survival. For each biomarker, a threshold value was identified, which proved useful to classify patients into groups having titers above or below the thresholds. We then stratified patients according to the two dichotomous variables into good-, intermediate-, and poor-risk groups, and found significantly different progression-free survival rates ranging from 3.5 to 11.6 months. Both VEGF and NGAL maintained their predictive significance at bivariate analysis. Our study shows that serum levels of VEGF and NGAL are significant predictors of progression-free survival in patients with renal cell carcinoma treated with sunitinib.

AB - To identify factors that might predict response to sunitinib in patients with renal cell carcinoma, we measured serum vascular endothelial growth factor (VEGF) and neutrophil gelatinase-associated lipocalin (NGAL) levels. A total of 85 patients were selected and, using the Motzer classification, 46 were assigned to the good-and 38 to the intermediate-risk groups. With univariate Cox analysis, both baseline serum VEGF and NGAL titers, determined by enzyme-linked immunosorbent assay, significantly predicted progression-free survival. For each biomarker, a threshold value was identified, which proved useful to classify patients into groups having titers above or below the thresholds. We then stratified patients according to the two dichotomous variables into good-, intermediate-, and poor-risk groups, and found significantly different progression-free survival rates ranging from 3.5 to 11.6 months. Both VEGF and NGAL maintained their predictive significance at bivariate analysis. Our study shows that serum levels of VEGF and NGAL are significant predictors of progression-free survival in patients with renal cell carcinoma treated with sunitinib.

KW - NGAL

KW - Predictive factors

KW - RCC

KW - Sunitinib

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=77951093888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951093888&partnerID=8YFLogxK

U2 - 10.1038/ki.2009.552

DO - 10.1038/ki.2009.552

M3 - Article

C2 - 20147887

AN - SCOPUS:77951093888

VL - 77

SP - 809

EP - 815

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 9

ER -